Redx Pharma’s FY21 results highlight notable achievement across all development activities, progressing both the in-house and out-licensed assets. Discovery efforts centre on the proven medicinal chemistry expertise, which is being focussed on the creation of “first in class” or “best in class” compounds that address well-defined cancers and fibrotic diseases. RXC004, a porcupine inhibitor for oncology, and RXC007, a ROCK2 inhibitor for fibrosis, are progressing through Phase II and Phase I trials respectively with further value inflection expected during 2022. Milestone payments received in FY21 and post-period end from AstraZeneca and Jazz Pharmaceuticals are tangible reminders of the value inherent in Redx Pharma’s discovery platform. Our rNPV-based valuation is £434m, equivalent to 157.5p/share.
27 Jan 2022
FY21 results: a year of continuing delivery
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
FY21 results: a year of continuing delivery
Redx Pharma Plc (REDX:LON) | 11.8 -0.1 (-7.8%) | Mkt Cap: 45.7m
- Published:
27 Jan 2022 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
13
Redx Pharma’s FY21 results highlight notable achievement across all development activities, progressing both the in-house and out-licensed assets. Discovery efforts centre on the proven medicinal chemistry expertise, which is being focussed on the creation of “first in class” or “best in class” compounds that address well-defined cancers and fibrotic diseases. RXC004, a porcupine inhibitor for oncology, and RXC007, a ROCK2 inhibitor for fibrosis, are progressing through Phase II and Phase I trials respectively with further value inflection expected during 2022. Milestone payments received in FY21 and post-period end from AstraZeneca and Jazz Pharmaceuticals are tangible reminders of the value inherent in Redx Pharma’s discovery platform. Our rNPV-based valuation is £434m, equivalent to 157.5p/share.